Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects

Targeting host factors exploited by multiple viruses could offer broad-spectrum solutions for pandemic preparedness. Seventeen candidates targeting diverse functions emerged in a screen of 4,413 compounds for SARS-CoV-2 inhibitors. We demonstrated that lapatinib and other approved inhibitors of the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JOURNAL OF CLINICAL INVESTIGATION 2023-10, Vol.133 (19)
Hauptverfasser: Saul, Sirle, Huie, Kathleen E, Tindle, Courtney, Sibai, Mamdouh, Ye, Chengjin, Khalil, Ahmed Magdy, Chiem, Kevin, Martinez-Sobrido, Luis, Dye, John M, Pinsky, Benjamin A, Ghosh, Pradipta, Das, Soumita, Solow-Cordero, David E, Jin, Jing, Wikswo, John P, Jochmans, Dirk, Neyts, Johan, De Jonghe, Steven, Narayanan, Aarthi, Einav, Shirit, Karim, Marwah, Ghita, Luca, Huang, Pei-Tzu, Chiu, Winston, Duran, Veronica, Lo, Chieh-Wen, Kumar, Sathish, Bhalla, Nishank, Leyssen, Pieter, Alem, Farhang, Boghdeh, Niloufar A, Tran, Do H.N, Cohen, Courtney A, Brown, Jacquelyn A
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 19
container_start_page
container_title JOURNAL OF CLINICAL INVESTIGATION
container_volume 133
creator Saul, Sirle
Huie, Kathleen E
Tindle, Courtney
Sibai, Mamdouh
Ye, Chengjin
Khalil, Ahmed Magdy
Chiem, Kevin
Martinez-Sobrido, Luis
Dye, John M
Pinsky, Benjamin A
Ghosh, Pradipta
Das, Soumita
Solow-Cordero, David E
Jin, Jing
Wikswo, John P
Jochmans, Dirk
Neyts, Johan
De Jonghe, Steven
Narayanan, Aarthi
Einav, Shirit
Karim, Marwah
Ghita, Luca
Huang, Pei-Tzu
Chiu, Winston
Duran, Veronica
Lo, Chieh-Wen
Kumar, Sathish
Bhalla, Nishank
Leyssen, Pieter
Alem, Farhang
Boghdeh, Niloufar A
Tran, Do H.N
Cohen, Courtney A
Brown, Jacquelyn A
description Targeting host factors exploited by multiple viruses could offer broad-spectrum solutions for pandemic preparedness. Seventeen candidates targeting diverse functions emerged in a screen of 4,413 compounds for SARS-CoV-2 inhibitors. We demonstrated that lapatinib and other approved inhibitors of the ErbB family of receptor tyrosine kinases suppress replication of SARS-CoV-2, Venezuelan equine encephalitis virus (VEEV), and other emerging viruses with a high barrier to resistance. Lapatinib suppressed SARS-CoV-2 entry and later stages of the viral life cycle and showed synergistic effect with the direct-acting antiviral nirmatrelvir. We discovered that ErbB1, ErbB2, and ErbB4 bind SARS-CoV-2 S1 protein and regulate viral and ACE2 internalization, and they are required for VEEV infection. In human lung organoids, lapatinib protected from SARS-CoV-2-induced activation of ErbB-regulated pathways implicated in non-infectious lung injury, proinflammatory cytokine production, and epithelial barrier injury. Lapatinib suppressed VEEV replication, cytokine production, and disruption of blood-brain barrier integrity in microfluidics-based human neurovascular units, and reduced mortality in a lethal infection murine model. We validated lapatinib-mediated inhibition of ErbB activity as an important mechanism of antiviral action. These findings reveal regulation of viral replication, inflammation, and tissue injury via ErbBs and establish a proof of principle for a repurposed, ErbB-targeted approach to combat emerging viruses.
format Article
fullrecord <record><control><sourceid>kuleuven</sourceid><recordid>TN_cdi_kuleuven_dspace_20_500_12942_727275</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20_500_12942_727275</sourcerecordid><originalsourceid>FETCH-kuleuven_dspace_20_500_12942_7272753</originalsourceid><addsrcrecordid>eNqVzE1qwzAQBWAtUsjvHbQOOMiyTZplUhJ6gO7FWB4TpbZsZkYhvX3d0AO0zOLB9x4zUwtjbJ4d9sXrXC2Zb8bkZVmVCzUcowQP0SPpEWJ2pvqkQ7yGOshArAmb5HGStoO-BwlD1BAbLYE5_fgt0ddT8IEkuqYBmoxH9EKpnwoJ90DQaWzbyXitXlroGDe_uVLby_nj7T37TB2mO0bX8AgenTWuMsbl9lBat7fTVcVK7f48dvKQ4l_fvwG4fVvw</addsrcrecordid><sourcetype>Institutional Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects</title><source>PubMed (Medline)</source><source>Lirias (KU Leuven Association)</source><source>Free E-Journal (出版社公開部分のみ)</source><source>Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><creator>Saul, Sirle ; Huie, Kathleen E ; Tindle, Courtney ; Sibai, Mamdouh ; Ye, Chengjin ; Khalil, Ahmed Magdy ; Chiem, Kevin ; Martinez-Sobrido, Luis ; Dye, John M ; Pinsky, Benjamin A ; Ghosh, Pradipta ; Das, Soumita ; Solow-Cordero, David E ; Jin, Jing ; Wikswo, John P ; Jochmans, Dirk ; Neyts, Johan ; De Jonghe, Steven ; Narayanan, Aarthi ; Einav, Shirit ; Karim, Marwah ; Ghita, Luca ; Huang, Pei-Tzu ; Chiu, Winston ; Duran, Veronica ; Lo, Chieh-Wen ; Kumar, Sathish ; Bhalla, Nishank ; Leyssen, Pieter ; Alem, Farhang ; Boghdeh, Niloufar A ; Tran, Do H.N ; Cohen, Courtney A ; Brown, Jacquelyn A</creator><creatorcontrib>Saul, Sirle ; Huie, Kathleen E ; Tindle, Courtney ; Sibai, Mamdouh ; Ye, Chengjin ; Khalil, Ahmed Magdy ; Chiem, Kevin ; Martinez-Sobrido, Luis ; Dye, John M ; Pinsky, Benjamin A ; Ghosh, Pradipta ; Das, Soumita ; Solow-Cordero, David E ; Jin, Jing ; Wikswo, John P ; Jochmans, Dirk ; Neyts, Johan ; De Jonghe, Steven ; Narayanan, Aarthi ; Einav, Shirit ; Karim, Marwah ; Ghita, Luca ; Huang, Pei-Tzu ; Chiu, Winston ; Duran, Veronica ; Lo, Chieh-Wen ; Kumar, Sathish ; Bhalla, Nishank ; Leyssen, Pieter ; Alem, Farhang ; Boghdeh, Niloufar A ; Tran, Do H.N ; Cohen, Courtney A ; Brown, Jacquelyn A</creatorcontrib><description>Targeting host factors exploited by multiple viruses could offer broad-spectrum solutions for pandemic preparedness. Seventeen candidates targeting diverse functions emerged in a screen of 4,413 compounds for SARS-CoV-2 inhibitors. We demonstrated that lapatinib and other approved inhibitors of the ErbB family of receptor tyrosine kinases suppress replication of SARS-CoV-2, Venezuelan equine encephalitis virus (VEEV), and other emerging viruses with a high barrier to resistance. Lapatinib suppressed SARS-CoV-2 entry and later stages of the viral life cycle and showed synergistic effect with the direct-acting antiviral nirmatrelvir. We discovered that ErbB1, ErbB2, and ErbB4 bind SARS-CoV-2 S1 protein and regulate viral and ACE2 internalization, and they are required for VEEV infection. In human lung organoids, lapatinib protected from SARS-CoV-2-induced activation of ErbB-regulated pathways implicated in non-infectious lung injury, proinflammatory cytokine production, and epithelial barrier injury. Lapatinib suppressed VEEV replication, cytokine production, and disruption of blood-brain barrier integrity in microfluidics-based human neurovascular units, and reduced mortality in a lethal infection murine model. We validated lapatinib-mediated inhibition of ErbB activity as an important mechanism of antiviral action. These findings reveal regulation of viral replication, inflammation, and tissue injury via ErbBs and establish a proof of principle for a repurposed, ErbB-targeted approach to combat emerging viruses.</description><identifier>ISSN: 0021-9738</identifier><language>eng</language><publisher>AMER SOC CLINICAL INVESTIGATION INC</publisher><ispartof>JOURNAL OF CLINICAL INVESTIGATION, 2023-10, Vol.133 (19)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,315,780,784,27860</link.rule.ids></links><search><creatorcontrib>Saul, Sirle</creatorcontrib><creatorcontrib>Huie, Kathleen E</creatorcontrib><creatorcontrib>Tindle, Courtney</creatorcontrib><creatorcontrib>Sibai, Mamdouh</creatorcontrib><creatorcontrib>Ye, Chengjin</creatorcontrib><creatorcontrib>Khalil, Ahmed Magdy</creatorcontrib><creatorcontrib>Chiem, Kevin</creatorcontrib><creatorcontrib>Martinez-Sobrido, Luis</creatorcontrib><creatorcontrib>Dye, John M</creatorcontrib><creatorcontrib>Pinsky, Benjamin A</creatorcontrib><creatorcontrib>Ghosh, Pradipta</creatorcontrib><creatorcontrib>Das, Soumita</creatorcontrib><creatorcontrib>Solow-Cordero, David E</creatorcontrib><creatorcontrib>Jin, Jing</creatorcontrib><creatorcontrib>Wikswo, John P</creatorcontrib><creatorcontrib>Jochmans, Dirk</creatorcontrib><creatorcontrib>Neyts, Johan</creatorcontrib><creatorcontrib>De Jonghe, Steven</creatorcontrib><creatorcontrib>Narayanan, Aarthi</creatorcontrib><creatorcontrib>Einav, Shirit</creatorcontrib><creatorcontrib>Karim, Marwah</creatorcontrib><creatorcontrib>Ghita, Luca</creatorcontrib><creatorcontrib>Huang, Pei-Tzu</creatorcontrib><creatorcontrib>Chiu, Winston</creatorcontrib><creatorcontrib>Duran, Veronica</creatorcontrib><creatorcontrib>Lo, Chieh-Wen</creatorcontrib><creatorcontrib>Kumar, Sathish</creatorcontrib><creatorcontrib>Bhalla, Nishank</creatorcontrib><creatorcontrib>Leyssen, Pieter</creatorcontrib><creatorcontrib>Alem, Farhang</creatorcontrib><creatorcontrib>Boghdeh, Niloufar A</creatorcontrib><creatorcontrib>Tran, Do H.N</creatorcontrib><creatorcontrib>Cohen, Courtney A</creatorcontrib><creatorcontrib>Brown, Jacquelyn A</creatorcontrib><title>Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects</title><title>JOURNAL OF CLINICAL INVESTIGATION</title><description>Targeting host factors exploited by multiple viruses could offer broad-spectrum solutions for pandemic preparedness. Seventeen candidates targeting diverse functions emerged in a screen of 4,413 compounds for SARS-CoV-2 inhibitors. We demonstrated that lapatinib and other approved inhibitors of the ErbB family of receptor tyrosine kinases suppress replication of SARS-CoV-2, Venezuelan equine encephalitis virus (VEEV), and other emerging viruses with a high barrier to resistance. Lapatinib suppressed SARS-CoV-2 entry and later stages of the viral life cycle and showed synergistic effect with the direct-acting antiviral nirmatrelvir. We discovered that ErbB1, ErbB2, and ErbB4 bind SARS-CoV-2 S1 protein and regulate viral and ACE2 internalization, and they are required for VEEV infection. In human lung organoids, lapatinib protected from SARS-CoV-2-induced activation of ErbB-regulated pathways implicated in non-infectious lung injury, proinflammatory cytokine production, and epithelial barrier injury. Lapatinib suppressed VEEV replication, cytokine production, and disruption of blood-brain barrier integrity in microfluidics-based human neurovascular units, and reduced mortality in a lethal infection murine model. We validated lapatinib-mediated inhibition of ErbB activity as an important mechanism of antiviral action. These findings reveal regulation of viral replication, inflammation, and tissue injury via ErbBs and establish a proof of principle for a repurposed, ErbB-targeted approach to combat emerging viruses.</description><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>FZOIL</sourceid><recordid>eNqVzE1qwzAQBWAtUsjvHbQOOMiyTZplUhJ6gO7FWB4TpbZsZkYhvX3d0AO0zOLB9x4zUwtjbJ4d9sXrXC2Zb8bkZVmVCzUcowQP0SPpEWJ2pvqkQ7yGOshArAmb5HGStoO-BwlD1BAbLYE5_fgt0ddT8IEkuqYBmoxH9EKpnwoJ90DQaWzbyXitXlroGDe_uVLby_nj7T37TB2mO0bX8AgenTWuMsbl9lBat7fTVcVK7f48dvKQ4l_fvwG4fVvw</recordid><startdate>20231002</startdate><enddate>20231002</enddate><creator>Saul, Sirle</creator><creator>Huie, Kathleen E</creator><creator>Tindle, Courtney</creator><creator>Sibai, Mamdouh</creator><creator>Ye, Chengjin</creator><creator>Khalil, Ahmed Magdy</creator><creator>Chiem, Kevin</creator><creator>Martinez-Sobrido, Luis</creator><creator>Dye, John M</creator><creator>Pinsky, Benjamin A</creator><creator>Ghosh, Pradipta</creator><creator>Das, Soumita</creator><creator>Solow-Cordero, David E</creator><creator>Jin, Jing</creator><creator>Wikswo, John P</creator><creator>Jochmans, Dirk</creator><creator>Neyts, Johan</creator><creator>De Jonghe, Steven</creator><creator>Narayanan, Aarthi</creator><creator>Einav, Shirit</creator><creator>Karim, Marwah</creator><creator>Ghita, Luca</creator><creator>Huang, Pei-Tzu</creator><creator>Chiu, Winston</creator><creator>Duran, Veronica</creator><creator>Lo, Chieh-Wen</creator><creator>Kumar, Sathish</creator><creator>Bhalla, Nishank</creator><creator>Leyssen, Pieter</creator><creator>Alem, Farhang</creator><creator>Boghdeh, Niloufar A</creator><creator>Tran, Do H.N</creator><creator>Cohen, Courtney A</creator><creator>Brown, Jacquelyn A</creator><general>AMER SOC CLINICAL INVESTIGATION INC</general><scope>FZOIL</scope></search><sort><creationdate>20231002</creationdate><title>Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects</title><author>Saul, Sirle ; Huie, Kathleen E ; Tindle, Courtney ; Sibai, Mamdouh ; Ye, Chengjin ; Khalil, Ahmed Magdy ; Chiem, Kevin ; Martinez-Sobrido, Luis ; Dye, John M ; Pinsky, Benjamin A ; Ghosh, Pradipta ; Das, Soumita ; Solow-Cordero, David E ; Jin, Jing ; Wikswo, John P ; Jochmans, Dirk ; Neyts, Johan ; De Jonghe, Steven ; Narayanan, Aarthi ; Einav, Shirit ; Karim, Marwah ; Ghita, Luca ; Huang, Pei-Tzu ; Chiu, Winston ; Duran, Veronica ; Lo, Chieh-Wen ; Kumar, Sathish ; Bhalla, Nishank ; Leyssen, Pieter ; Alem, Farhang ; Boghdeh, Niloufar A ; Tran, Do H.N ; Cohen, Courtney A ; Brown, Jacquelyn A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-kuleuven_dspace_20_500_12942_7272753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saul, Sirle</creatorcontrib><creatorcontrib>Huie, Kathleen E</creatorcontrib><creatorcontrib>Tindle, Courtney</creatorcontrib><creatorcontrib>Sibai, Mamdouh</creatorcontrib><creatorcontrib>Ye, Chengjin</creatorcontrib><creatorcontrib>Khalil, Ahmed Magdy</creatorcontrib><creatorcontrib>Chiem, Kevin</creatorcontrib><creatorcontrib>Martinez-Sobrido, Luis</creatorcontrib><creatorcontrib>Dye, John M</creatorcontrib><creatorcontrib>Pinsky, Benjamin A</creatorcontrib><creatorcontrib>Ghosh, Pradipta</creatorcontrib><creatorcontrib>Das, Soumita</creatorcontrib><creatorcontrib>Solow-Cordero, David E</creatorcontrib><creatorcontrib>Jin, Jing</creatorcontrib><creatorcontrib>Wikswo, John P</creatorcontrib><creatorcontrib>Jochmans, Dirk</creatorcontrib><creatorcontrib>Neyts, Johan</creatorcontrib><creatorcontrib>De Jonghe, Steven</creatorcontrib><creatorcontrib>Narayanan, Aarthi</creatorcontrib><creatorcontrib>Einav, Shirit</creatorcontrib><creatorcontrib>Karim, Marwah</creatorcontrib><creatorcontrib>Ghita, Luca</creatorcontrib><creatorcontrib>Huang, Pei-Tzu</creatorcontrib><creatorcontrib>Chiu, Winston</creatorcontrib><creatorcontrib>Duran, Veronica</creatorcontrib><creatorcontrib>Lo, Chieh-Wen</creatorcontrib><creatorcontrib>Kumar, Sathish</creatorcontrib><creatorcontrib>Bhalla, Nishank</creatorcontrib><creatorcontrib>Leyssen, Pieter</creatorcontrib><creatorcontrib>Alem, Farhang</creatorcontrib><creatorcontrib>Boghdeh, Niloufar A</creatorcontrib><creatorcontrib>Tran, Do H.N</creatorcontrib><creatorcontrib>Cohen, Courtney A</creatorcontrib><creatorcontrib>Brown, Jacquelyn A</creatorcontrib><collection>Lirias (KU Leuven Association)</collection><jtitle>JOURNAL OF CLINICAL INVESTIGATION</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saul, Sirle</au><au>Huie, Kathleen E</au><au>Tindle, Courtney</au><au>Sibai, Mamdouh</au><au>Ye, Chengjin</au><au>Khalil, Ahmed Magdy</au><au>Chiem, Kevin</au><au>Martinez-Sobrido, Luis</au><au>Dye, John M</au><au>Pinsky, Benjamin A</au><au>Ghosh, Pradipta</au><au>Das, Soumita</au><au>Solow-Cordero, David E</au><au>Jin, Jing</au><au>Wikswo, John P</au><au>Jochmans, Dirk</au><au>Neyts, Johan</au><au>De Jonghe, Steven</au><au>Narayanan, Aarthi</au><au>Einav, Shirit</au><au>Karim, Marwah</au><au>Ghita, Luca</au><au>Huang, Pei-Tzu</au><au>Chiu, Winston</au><au>Duran, Veronica</au><au>Lo, Chieh-Wen</au><au>Kumar, Sathish</au><au>Bhalla, Nishank</au><au>Leyssen, Pieter</au><au>Alem, Farhang</au><au>Boghdeh, Niloufar A</au><au>Tran, Do H.N</au><au>Cohen, Courtney A</au><au>Brown, Jacquelyn A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects</atitle><jtitle>JOURNAL OF CLINICAL INVESTIGATION</jtitle><date>2023-10-02</date><risdate>2023</risdate><volume>133</volume><issue>19</issue><issn>0021-9738</issn><abstract>Targeting host factors exploited by multiple viruses could offer broad-spectrum solutions for pandemic preparedness. Seventeen candidates targeting diverse functions emerged in a screen of 4,413 compounds for SARS-CoV-2 inhibitors. We demonstrated that lapatinib and other approved inhibitors of the ErbB family of receptor tyrosine kinases suppress replication of SARS-CoV-2, Venezuelan equine encephalitis virus (VEEV), and other emerging viruses with a high barrier to resistance. Lapatinib suppressed SARS-CoV-2 entry and later stages of the viral life cycle and showed synergistic effect with the direct-acting antiviral nirmatrelvir. We discovered that ErbB1, ErbB2, and ErbB4 bind SARS-CoV-2 S1 protein and regulate viral and ACE2 internalization, and they are required for VEEV infection. In human lung organoids, lapatinib protected from SARS-CoV-2-induced activation of ErbB-regulated pathways implicated in non-infectious lung injury, proinflammatory cytokine production, and epithelial barrier injury. Lapatinib suppressed VEEV replication, cytokine production, and disruption of blood-brain barrier integrity in microfluidics-based human neurovascular units, and reduced mortality in a lethal infection murine model. We validated lapatinib-mediated inhibition of ErbB activity as an important mechanism of antiviral action. These findings reveal regulation of viral replication, inflammation, and tissue injury via ErbBs and establish a proof of principle for a repurposed, ErbB-targeted approach to combat emerging viruses.</abstract><pub>AMER SOC CLINICAL INVESTIGATION INC</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof JOURNAL OF CLINICAL INVESTIGATION, 2023-10, Vol.133 (19)
issn 0021-9738
language eng
recordid cdi_kuleuven_dspace_20_500_12942_727275
source PubMed (Medline); Lirias (KU Leuven Association); Free E-Journal (出版社公開部分のみ); Directory of Open Access Journals; Alma/SFX Local Collection
title Anticancer pan-ErbB inhibitors reduce inflammation and tissue injury and exert broad-spectrum antiviral effects
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A27%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-kuleuven&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anticancer%20pan-ErbB%20inhibitors%20reduce%20inflammation%20and%20tissue%20injury%20and%20exert%20broad-spectrum%20antiviral%20effects&rft.jtitle=JOURNAL%20OF%20CLINICAL%20INVESTIGATION&rft.au=Saul,%20Sirle&rft.date=2023-10-02&rft.volume=133&rft.issue=19&rft.issn=0021-9738&rft_id=info:doi/&rft_dat=%3Ckuleuven%3E20_500_12942_727275%3C/kuleuven%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true